Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd

Reuters03-30

March 30 (Reuters) - Connect Biopharma Holdings Ltd ::
*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD
*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD
*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART 300 MG IV PUSH PRODUCES RAPID FEV1 IMPROVEMENT ≥200 ML IN ASTHMA AND COPD
*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS
*CONNECT BIOPHARMA HOLDINGS LTD - RECRUITMENT ONGOING FOR PHASE 2 SEABREEZE STAT STUDIES; TOPLINE DATA EXPECTED MID-2026

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 30-MAR-202611:00:01.683 GMT

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623345388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623345388","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd","media":"Reuters","content":"<html><body>March 30 (Reuters) - <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Holdings Ltd <cntb.o>::<br/>*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD<br/>*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART 300 MG IV PUSH PRODUCES RAPID FEV1 IMPROVEMENT ≥200 ML IN ASTHMA AND COPD<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RECRUITMENT ONGOING FOR PHASE 2 SEABREEZE STAT STUDIES; TOPLINE DATA EXPECTED MID-2026<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 30-MAR-202611:00:01.683 GMT</cntb.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>March 30 (Reuters) - <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Holdings Ltd <cntb.o>::<br/>*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD<br/>*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART 300 MG IV PUSH PRODUCES RAPID FEV1 IMPROVEMENT ≥200 ML IN ASTHMA AND COPD<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS<br/>*CONNECT BIOPHARMA HOLDINGS LTD - RECRUITMENT ONGOING FOR PHASE 2 SEABREEZE STAT STUDIES; TOPLINE DATA EXPECTED MID-2026<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 30-MAR-202611:00:01.683 GMT</cntb.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nRSD22z7kv:1","article_id":"2623345388","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623345388","pubTimestamp":1774877664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"March 30 (Reuters) - Connect Biopharma Holdings Ltd ::*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD*CONNECT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CNTB":"康乃德生物医药"},"translate_title":"Connect Biopharma宣布其静脉注射(Iv)Rademikibart治疗哮喘或Copd患者的1期研究的积极顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9},"content_text":"March 30 (Reuters) - Connect Biopharma Holdings Ltd ::*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART 300 MG IV PUSH PRODUCES RAPID FEV1 IMPROVEMENT ≥200 ML IN ASTHMA AND COPD*CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS*CONNECT BIOPHARMA HOLDINGS LTD - RECRUITMENT ONGOING FOR PHASE 2 SEABREEZE STAT STUDIES; TOPLINE DATA EXPECTED MID-2026  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-MAR-202611:00:01.683 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623345388","isCrawlerRequest":true}